Pharma Mar, S.A. (BME:PHM)
Spain · Delayed Price · Currency is EUR | Market Cap | 1.21B -5.0% |
| Revenue (ttm) | 218.64M +15.5% |
| Net Income | 56.13M +33.6% |
| EPS | 3.11 +29.1% |
| Shares Out | 17.34M |
| PE Ratio | 22.51 |
| Forward PE | 18.17 |
| Dividend | 1.00 (1.43%) |
| Ex-Dividend Date | Jul 8, 2026 |
| Volume | 10,644 |
| Open | 68.40 |
| Previous Close | 68.05 |
| Day's Range | 67.95 - 70.05 |
| 52-Week Range | 64.00 - 105.20 |
| Beta | 0.47 |
| Analysts | Buy |
| Price Target | 102.44 (+46.24%) |
| Est. Earnings | Oct 29, 2026 |
About Pharma Mar
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to... [Read more]
Financial Performance
In 2025, Pharma Mar's revenue was 221.39 million, an increase of 26.61% compared to the previous year's 174.86 million. Earnings were 74.99 million, an increase of 187.03%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for PHM stock is "Buy." The 12-month stock price target is €102.44, which is an increase of 46.24% from the latest price.
News
Pharma Mar Transcript: Chardan's 10th Annual Healthcare Conference
Germany and Austria launches of lurbinectedin–atezolizumab were described as ahead of expectations, with broader European reimbursement expected within a year. Focus also turned to tarlatamab sequencing, LAGOON’s failed endpoint and a H1 2027 SaLuDo readout.
Pharma Mar Slides: Corporate presentation
Pharma Mar has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Pharma Mar Earnings Call Transcript: Q2 2026
Recurring revenues grew strongly in H1 2026, driven by Zepzelca's U.S. royalties and early European launch, offsetting prior year non-recurring items. Cash flow and net cash improved, with rapid EU market access and further revenue growth expected in H2.
Pharma Mar Earnings release: Q2 2026
Pharma Mar released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Pharma Mar Quarterly report: Q2 2026
Pharma Mar has published its Q2 2026 quarterly earnings report on July 30, 2026.
Pharma Mar price target lowered to EUR 100 from EUR 120 at Chardan
Chardan lowered the firm’s price target on Pharma Mar (PHMMF) to EUR 100 from EUR 120 and keeps a Buy rating on the shares after the Phase III LAGOON trial…
Pharma Mar Earnings release: Q1 2026
Pharma Mar released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Pharma Mar Quarterly report: Q1 2026
Pharma Mar has published its Q1 2026 quarterly earnings report on April 29, 2026.
Pharma Mar initiated with a Buy at BTIG
BTIG initiated coverage of Pharma Mar (PHMMF) with a Buy rating and EUR 121 price target The current valuation is anchored by a “profitable, cash-generative commercial base” driven by Zepzelca’s…
Pharma Mar Slides: Corporate presentation
Pharma Mar has posted slides in relation to its latest quarterly earnings report, which was published on April 2, 2026.
Pharma Mar Slides: Corporate presentation
Pharma Mar has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
Pharma Mar Earnings Call Transcript: Q4 2025
2025 saw 27% revenue growth, a fivefold EBITDA increase, and major milestones for Zepzelca, including U.S. first-line approval. Strong cash flow and pipeline progress position the company for further growth in 2026.
Pharma Mar Earnings release: Q4 2025
Pharma Mar released its Q4 2025 earnings on February 27, 2026, summarizing the period's financial results.
Pharma Mar Quarterly report: Q4 2025
Pharma Mar has published its Q4 2025 quarterly earnings report on February 27, 2026.
Pharma Mar Earnings release: Q3 2025
Pharma Mar released its Q3 2025 earnings on October 30, 2025, summarizing the period's financial results.
Pharma Mar Quarterly report: Q3 2025
Pharma Mar has published its Q3 2025 quarterly earnings report on October 30, 2025.
Pharma Mar Earnings Call Transcript: Q2 2025
Revenues grew 18% year-over-year, driven by strong oncology sales and major licensing deals. EBITDA reached EUR 25 million, net profit EUR 19.4 million, and ZEPZELCA saw significant progress in Europe, China, and regulatory filings.
Pharma Mar Earnings release: Q2 2025
Pharma Mar released its Q2 2025 earnings on July 31, 2025, summarizing the period's financial results.
Pharma Mar Quarterly report: Q2 2025
Pharma Mar has published its Q2 2025 quarterly earnings report on July 31, 2025.
Pharma Mar Transcript: Status Update
IMforte data for lurbinectedin maintenance in small cell lung cancer are seen as practice-changing, offering meaningful survival benefits and manageable toxicity. Rapid adoption is expected in Europe, though future competition from tarlatamab may impact its long-term role.
Pharma Mar Press release: Status Update
Pharma Mar issued a press release on June 12, 2025, disclosing material business information to investors.
Pharma Mar Slides: Status Update
Pharma Mar has posted slides in relation to its latest quarterly earnings report, which was published on June 12, 2025.
Pharma Mar Earnings release: Q1 2025
Pharma Mar released its Q1 2025 earnings on April 24, 2025, summarizing the period's financial results.
Pharma Mar Quarterly report: Q1 2025
Pharma Mar has published its Q1 2025 quarterly earnings report on April 24, 2025.
Pharma Mar Earnings Call Transcript: Q4 2024
Double-digit revenue growth in 2024 was driven by Sapselca and Yondelis, with EBITDA rising to EUR 13 million and net profit to EUR 26.2 million. Positive clinical milestones and strong cash position support future growth, with regulatory submissions and new launches expected in 2025.